ASH 2025: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know
He describes the science behind ITK, and goes over ASH data in r/r T-cell lymphoma, where the company is already enrolling a pivotal study. Plus, why the profile of ITK in oncology gives him confidence in its utility for autoimmune disease, and highlighting atopic dermatitis data that will be coming in January.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.